8-K: CytoSorbents Pursues Expedited DrugSorb-ATR FDA Path

CytoSorbents Corporation announced a regulatory update for DrugSorb-ATR, outlining a new expedited path with the FDA for market authorization after an appeal decision.

Summary

• The FDA appeal decision regarding DrugSorb-ATR's De Novo application upheld the prior denial, citing the need for additional information to support the desired label indication.
• The FDA found no issues with DrugSorb-ATR device safety.
• The FDA proactively proposed a potential expedited path forward for market authorization.
• The Company decided against a final appeal to the Director of CDRH due to positive FDA upper management feedback for a reasonable and potentially expedited De Novo grant for the original desired label indication.
• Plans are in place to file a new De Novo application with additional analyses of new real-world data, which was not available at the time of the original submission.
• The new submission review is expected to focus only on the remaining open items from the initial De Novo submission, with no safety issues identified previously.
• The new application is expected to be reviewed in an expedited fashion under the Breakthrough Device Designation.
• The Request for Reconsideration with Health Canada was withdrawn, and a new Medical Device License application will be provided after better clarity is received from the U.S. FDA.
• The Company aims to manage its core business to near breakeven as it exits 2025 by focusing on growth in key clinical applications, improving product gross margins, controlling costs, and driving efficiencies.

Sentiment

Score: 6

Explanation: While the FDA upheld its initial denial, the proactive proposal of an expedited path, positive upper management feedback, and the absence of safety concerns for DrugSorb-ATR are encouraging. The company's plan to submit new real-world data and leverage its Breakthrough Device Designation suggests a strong commitment to securing approval. However, the U.S. approval is still pending, and the Health Canada process is delayed, introducing continued uncertainty and extending the timeline for market entry.

Positives

• The FDA found no issues with DrugSorb-ATR device safety during its prior review.
• The FDA proactively proposed a potential expedited path forward for market authorization for DrugSorb-ATR.
• Positive FDA upper management feedback was received for a reasonable and potentially expedited De Novo grant for the Company's original desired label indication.
• The Company plans to leverage new real-world data, drawn from a consistent patient population, which it believes reiterates robust clinical performance and strengthens the benefit-to-risk profile.
• The new FDA application is expected to be reviewed in an expedited fashion under the Breakthrough Device Designation, providing for priority and interactive review.
• The Company is committed to managing its core business to near breakeven by the end of 2025 through growth, margin improvement, and cost control.

Negatives

• The FDA upheld its prior De Novo denial decision for DrugSorb-ATR, requiring additional information for market authorization.
• Market authorization for DrugSorb-ATR in the U.S. is delayed beyond the original timeline, necessitating a new application and review process.
• The Health Canada regulatory review for DrugSorb-ATR is delayed, with the Company withdrawing its Request for Reconsideration and planning to submit a new application only after gaining clarity from the FDA.

Risks

• Inability to successfully obtain U.S. FDA and Health Canada marketing authorization or approval for DrugSorb-ATR.
• Inability to grow sales and cut costs effectively in the core business.
• Uncertain outcome of the restructuring of the direct sales team and strategy in Germany.
• Inability to appropriately finance the Company.
• General risks discussed in the Annual Report on Form 10-K filed with the SEC on March 31, 2025, and subsequent Quarterly Reports on Form 10-Q.

Future Outlook

The Company plans to file a new De Novo application with the FDA, expecting an expedited review under its Breakthrough Device Designation, with a standard regulatory decision anticipated in mid-2026. It also intends to refile with Health Canada after gaining clarity from the FDA. Management is focused on driving core business growth, improving gross margins, controlling costs, and achieving near breakeven by the end of 2025.

Management Comments

• "We are encouraged by the continued constructive dialogue with the FDA to define a clear and expedited path forward."
• "We plan to move as quickly as possible to have our pre-submission meeting with the FDA to finalize alignment and to file our new De Novo application, which is expected to heavily leverage our original filing."
• "We continue to have confidence in the performance and clinical value of DrugSorb-ATR for this major unmet medical need and the importance of making this FDA Breakthrough Designated Device available to the American public."
• "We remain committed to working collaboratively with both the FDA and Health Canada to secure marketing authorization for DrugSorb-ATR."
• "Meanwhile, we continue to be focused on driving growth in our core business with key, high impact clinical applications, improving product gross margins, controlling costs, and driving efficiencies to manage our core business to near breakeven as we exit 2025."

Industry Context

The blood purification industry, particularly for critical care and cardiac surgery, is highly regulated. CytoSorbents' DrugSorb-ATR, designed to remove blood thinners during urgent cardiothoracic procedures, addresses a significant unmet medical need. The FDA's Breakthrough Device Designation highlights the innovative nature and potential impact of the technology, positioning CytoSorbents as a key player in developing advanced solutions for perioperative bleeding management.

Comparison to Industry Standards

• The filing does not provide specific comparisons to other companies, projects, or results.
• DrugSorb-ATR has received two FDA Breakthrough Device Designations: one for the removal of ticagrelor and another for the removal of direct oral anticoagulants (DOAC) apixaban and rivaroxaban in a cardiopulmonary bypass circuit during urgent cardiothoracic procedures. This designation indicates that the device provides more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions, or addresses an unmet need, compared to existing alternatives, setting a high standard within the medical device industry.

Stakeholder Impact

• Shareholders: Continued uncertainty regarding DrugSorb-ATR's market approval timeline, but a clearer, expedited path forward could provide long-term value. Delays in market entry could impact revenue projections.
• Patients: Potential for a new treatment option for life-threatening conditions in cardiac surgery, once approved, offering improved outcomes by reducing perioperative bleeding.
• Healthcare Providers: Anticipation of a new tool for managing high-risk surgery patients on blood thinners, pending regulatory clearance.
• Employees: Continued focus on core business growth and efficiency to manage to near breakeven by end of 2025, suggesting stability but also cost control measures.

Next Steps

• File a pre-submission meeting request with supporting documentation to the FDA next month (approx. October 2025).
• Anticipate a formal meeting with the FDA in Q4 2025 to confirm requirements for the new De Novo submission.
• File a new De Novo application with additional real-world data.
• Expect a standard regulatory decision in mid-2026 following a timely De Novo submission and typical 150-day review process.
• Provide a new Medical Device License application to Health Canada with improved visibility from the FDA.
• Continue focusing on driving growth in core business, improving product gross margins, controlling costs, and driving efficiencies to manage core business to near breakeven as of end of 2025.

Key Dates

Recommendation

While the FDA's proactive guidance and the absence of safety concerns for DrugSorb-ATR are positive developments, the continued delay in market authorization and the need for a new De Novo submission introduce ongoing uncertainty. The Health Canada process is also delayed. The company's commitment to achieving near breakeven in its core business by year-end is encouraging, but the path to significant revenue from DrugSorb-ATR is still some time away. Investors should hold to monitor the progress of the new FDA submission and the company's financial performance in its core business.

Keywords

CytoSorbents, DrugSorb-ATR, FDA, De Novo, Breakthrough Device, Regulatory Update, Blood Purification, Cardiothoracic Surgery, Ticagrelor, Antithrombotic, Health Canada, Medical Device